Promontory Therapeutics Inc., a clinical-stage biotechnology company specializing in immunogenic small molecule approaches in oncology, has achieved the distinction of being the first international company to gain membership in the Paris-Saclay Cancer Center (PSCC). PSCC is an emerging European hub for cancer research and innovation, and as a member, Promontory now has access to its extensive oncology community, including experts, technology platforms, facilities, and more. This membership will support Promontory's clinical progress in Europe, particularly in France, where its Phase 2 study of the immunogenic cancer cell death inducer PT-112 has recently expanded to clinical sites, led by the Gustave Roussy Paris.

Promontory's Chief Operating Officer, Matthew R. Price, expressed the company's honor in being selected as the first international member of the PSCC. This collaboration aims to accelerate innovation in cancer care and strengthen Promontory's presence in Europe.

Promontory initiated patient enrollment in France for its ongoing Phase 2 study of PT-112 in late-stage metastatic castration-resistant prostate cancer (mCRPC) in July 2023. This initiative is under the leadership of Gustave Roussy Paris, a founding institute of PSCC, along with other esteemed institutions like the Paris-Saclay University, the Polytechnic Institute of Paris, Inserm (the French National Institute of Health and Medical Research), and Sanofi.